Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread into the bladder muscle), confirmed through a surgical or biopsy procedure.
- People who have already started their first dose of a treatment called TAR-200 in a standard clinical (non-trial) setting within the 6 weeks before their first study visit.
- People of childbearing potential who are following the contraception recommendations outlined in the official TAR-200 product information, and who have spoken with their doctor about personalised contraceptive advice.
- People who have given their formal written consent to participate, as described in the study protocol.
Who may not be able to join:
- People whose doctor has determined that TAR-200 treatment is medically unsuitable for them for any reason.
- People whose TAR-200 treatment was stopped before their first study visit.
- People who have previously received TAR-200 delivered directly into the bladder as part of any clinical trial.
- People who have already received more than 2 doses or cycles of TAR-200 in a standard clinical (non-trial) setting.
- People who are currently taking part in another interventional clinical trial for bladder cancer.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Disease-Free Survival (DFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.